Effects of methotrexate and etanercept on c-reactive protein and anti-cyclic citrullinated peptide antibodies level in rheumatoid arthritis patients

المؤلفون المشاركون

Zuhayr, Khawlah H.
Jafar, Yasir Abd al-Husayn
Kubba, Rasha Husayn

المصدر

مجلة جامعة الكوفة لعلوم الحياة : مجلة علمية محكمة

الناشر

جامعة الكوفة كلية العلوم قسم علوم الحياة

تاريخ النشر

2016-12-31

دولة النشر

العراق

عدد الصفحات

5

التخصصات الرئيسية

الأحياء

الموضوعات

• الأجسام المضادة
• الببتيدات
• الذباب
• التهاب المفاصل الروماتويدي
• بروتين سي التفاعلي
• ذوات الجناحين(رتبة)

الملخص الإنجليزي

Rheumatoid Arthritis (RA) is an autoimmune disease.

The treatment of this disease by taking Etnercept and Methotrexate (MTX) drugs.

This study was conducted to detect C-Reactive Protein (C-RP) and Anti- Citrullinated Peptide Antibodies (Anti-CCP Abs) level among 126 rheumatoid arthritis (RA) patients treated with Etanercept (ETN) and methotrexate (MTX), 94 RA patients treated with MTX, 80 RA patients without treatment and 100 samples as healthy control.

Blood samples were collected and the presence of C-RP antibodies was determined by using Latex agglutination test (LAT).

Anti-CCP Abs was also estimated in serum of all subjects by using Enzyme linked immunosorbent assay (ELISA) method too.

The seroprevalence of C-RP in RA+ETN+MTX was 57(45.24%), in RA+MTX was 62(65.96%), in untreated RA patients was 53(66.25%) while, it was 5(5%)in healthy group.

The mean levels of Anti-CCP Abs in RA+ETN+MTX patients were (18.53± 1.70 pg/ml), in RA+MTX patients was (47.61± 6.24 pg/ml), and in untreated RA patients was (167.98 ± 8.67 pg/ml)while, they were (10.3 pg/ml ± 0.87) in healthy group.

The results showed significant difference (P<0.05) for both C-RP prevalence and Anti-CCP Abs serum levels was found between studied subjects.

نوع البيانات

أوراق مؤتمرات

رقم السجل

BIM-752839

• APA
• MLA
• AMA